Trials / Completed
CompletedNCT00921869
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
A Phase I Dose-finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally twice daily to patients with advanced solid tumors.
Detailed description
Phase I, open-label, dose-escalation study to determine the maximum tolerated dose (MTD) of E7050 given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7050 | The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-06-16
- Last updated
- 2017-12-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00921869. Inclusion in this directory is not an endorsement.